A Survey of Women's Perspective on Pursuing and Receiving Donor Eggs
(The TOTEM Study)
Women who wish to have children may be interested to know about their chances of pregnancy now and in the future. Anti-Müllerian Hormone (AMH) is a test that is increasingly offered and used as a measure of fertility. The test is often marketed as an empowering new technology that gives women personalised information about their fertility; but because this test cannot accurately predict fertility, results can be misleading.
This study will explore how AMH testing impacts women’s wellbeing and how it may influence their choices and behaviours around family planning. It aims to investigate whether AMH test results change women’s plans to become pregnant or lead to use of assisted reproductive technologies such as IVF and elective egg freezing.
A/Prof Michelle Peate (University of Melbourne, Royal Women's Hospital), Ms Anastasia Vakkas, (University of Melbourne), Dr Sarah Lensen, (University of Melbourne, Royal Women's Hospital), Dr Tessa Copp (University of Sydney), Dr Karin Hammarberg (Monash University and Victorian Assisted Reproductive Treatment Authority, Dr Magdalena Simonis (University of Melbourne), Dr Devora Lieberman (City Fertility), Ms Sherine Sandhu (University of Melbourne, Royal Women's Hospital)